Substance abuse (including nicotine) in schizophrenic patients

Joseph Patrick McEvoy, Trina B. Allen

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Purpose of review: Comorbid substance-use disorders are present in at least 25% of patients with schizophrenia, and 70-80% of these patients smoke. It is important to understand how substance-use disorders affect outcomes in this already impaired population. Recent findings: Substance-use disorders occur most commonly in males, and are most prevalent in the young. Substance-use disorders are associated with bad outcomes, including medication non-compliance, rehospitalization, homelessness, contact with the criminal justice system, medical morbidity and suicide, and these bad outcomes seem to be more likely among those patients who utilize multiple drugs rather than alcohol alone. Psychosocial and behavioral treatments produce few successes. Early indications suggest that clozapine may reduce substance-use disorders. Nicotine corrects certain neurophysiological deficits (e.g. eye-tracking abnormalities) in patients with schizophrenia. Maternal smoking during pregnancy may increase the likelihood of antisocial behavior and substance-use disorder in the offspring. Atypical antipsychotics plus bupropion increase the likelihood of smoking reduction/cessation in patients with schizophrenia. Summary: The recent literature clearly documents the devastating effects of comorbid substance-use disorders in schizophrenia. Promising new treatment options will require further study.

Original languageEnglish (US)
Pages (from-to)199-205
Number of pages7
JournalCurrent Opinion in Psychiatry
Volume16
Issue number2
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Nicotine
Substance-Related Disorders
Schizophrenia
Eye Abnormalities
Bupropion
Homeless Persons
Criminal Law
Medication Adherence
Clozapine
Smoking Cessation
Smoke
Suicide
Antipsychotic Agents
Smoking
Alcohols
Mothers
Morbidity
Pregnancy
Therapeutics
Pharmaceutical Preparations

Keywords

  • Nicotine
  • Schizophrenia
  • Smoking
  • Substance-use disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Substance abuse (including nicotine) in schizophrenic patients. / McEvoy, Joseph Patrick; Allen, Trina B.

In: Current Opinion in Psychiatry, Vol. 16, No. 2, 01.03.2003, p. 199-205.

Research output: Contribution to journalReview article

@article{2516ef52c8d544ce8d15087baf56c8c5,
title = "Substance abuse (including nicotine) in schizophrenic patients",
abstract = "Purpose of review: Comorbid substance-use disorders are present in at least 25{\%} of patients with schizophrenia, and 70-80{\%} of these patients smoke. It is important to understand how substance-use disorders affect outcomes in this already impaired population. Recent findings: Substance-use disorders occur most commonly in males, and are most prevalent in the young. Substance-use disorders are associated with bad outcomes, including medication non-compliance, rehospitalization, homelessness, contact with the criminal justice system, medical morbidity and suicide, and these bad outcomes seem to be more likely among those patients who utilize multiple drugs rather than alcohol alone. Psychosocial and behavioral treatments produce few successes. Early indications suggest that clozapine may reduce substance-use disorders. Nicotine corrects certain neurophysiological deficits (e.g. eye-tracking abnormalities) in patients with schizophrenia. Maternal smoking during pregnancy may increase the likelihood of antisocial behavior and substance-use disorder in the offspring. Atypical antipsychotics plus bupropion increase the likelihood of smoking reduction/cessation in patients with schizophrenia. Summary: The recent literature clearly documents the devastating effects of comorbid substance-use disorders in schizophrenia. Promising new treatment options will require further study.",
keywords = "Nicotine, Schizophrenia, Smoking, Substance-use disorders",
author = "McEvoy, {Joseph Patrick} and Allen, {Trina B.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1097/00001504-200303000-00010",
language = "English (US)",
volume = "16",
pages = "199--205",
journal = "Current Opinion in Psychiatry",
issn = "0951-7367",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Substance abuse (including nicotine) in schizophrenic patients

AU - McEvoy, Joseph Patrick

AU - Allen, Trina B.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Purpose of review: Comorbid substance-use disorders are present in at least 25% of patients with schizophrenia, and 70-80% of these patients smoke. It is important to understand how substance-use disorders affect outcomes in this already impaired population. Recent findings: Substance-use disorders occur most commonly in males, and are most prevalent in the young. Substance-use disorders are associated with bad outcomes, including medication non-compliance, rehospitalization, homelessness, contact with the criminal justice system, medical morbidity and suicide, and these bad outcomes seem to be more likely among those patients who utilize multiple drugs rather than alcohol alone. Psychosocial and behavioral treatments produce few successes. Early indications suggest that clozapine may reduce substance-use disorders. Nicotine corrects certain neurophysiological deficits (e.g. eye-tracking abnormalities) in patients with schizophrenia. Maternal smoking during pregnancy may increase the likelihood of antisocial behavior and substance-use disorder in the offspring. Atypical antipsychotics plus bupropion increase the likelihood of smoking reduction/cessation in patients with schizophrenia. Summary: The recent literature clearly documents the devastating effects of comorbid substance-use disorders in schizophrenia. Promising new treatment options will require further study.

AB - Purpose of review: Comorbid substance-use disorders are present in at least 25% of patients with schizophrenia, and 70-80% of these patients smoke. It is important to understand how substance-use disorders affect outcomes in this already impaired population. Recent findings: Substance-use disorders occur most commonly in males, and are most prevalent in the young. Substance-use disorders are associated with bad outcomes, including medication non-compliance, rehospitalization, homelessness, contact with the criminal justice system, medical morbidity and suicide, and these bad outcomes seem to be more likely among those patients who utilize multiple drugs rather than alcohol alone. Psychosocial and behavioral treatments produce few successes. Early indications suggest that clozapine may reduce substance-use disorders. Nicotine corrects certain neurophysiological deficits (e.g. eye-tracking abnormalities) in patients with schizophrenia. Maternal smoking during pregnancy may increase the likelihood of antisocial behavior and substance-use disorder in the offspring. Atypical antipsychotics plus bupropion increase the likelihood of smoking reduction/cessation in patients with schizophrenia. Summary: The recent literature clearly documents the devastating effects of comorbid substance-use disorders in schizophrenia. Promising new treatment options will require further study.

KW - Nicotine

KW - Schizophrenia

KW - Smoking

KW - Substance-use disorders

UR - http://www.scopus.com/inward/record.url?scp=0037336438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037336438&partnerID=8YFLogxK

U2 - 10.1097/00001504-200303000-00010

DO - 10.1097/00001504-200303000-00010

M3 - Review article

AN - SCOPUS:0037336438

VL - 16

SP - 199

EP - 205

JO - Current Opinion in Psychiatry

JF - Current Opinion in Psychiatry

SN - 0951-7367

IS - 2

ER -